These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21317602)

  • 1. Policy implications of integrating buprenorphine/naloxone treatment and HIV care.
    Finkelstein R; Netherland J; Sylla L; Gourevitch MN; Cajina A; Cheever L;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S98-S104. PubMed ID: 21317602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment.
    Weiss L; Egan JE; Botsko M; Netherland J; Fiellin DA; Finkelstein R
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S7-13. PubMed ID: 21317598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
    Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
    Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of integrated HIV care and buprenorphine/naloxone treatment: results of a cross-site evaluation.
    Schackman BR; Leff JA; Botsko M; Fiellin DA; Altice FL; Korthuis PT; Sohler N; Weiss L; Egan JE; Netherland J; Gass J; Finkelstein R;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S76-82. PubMed ID: 21317599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
    Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care.
    Schackman BR; Merrill JO; McCarty D; Levi J; Lubinski C
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S247-53. PubMed ID: 17109311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care.
    Egan JE; Netherland J; Gass J; Finkelstein R; Weiss L;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S46-53. PubMed ID: 21317594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
    Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients.
    Edelman EJ; Chantarat T; Caffrey S; Chaudhry A; O'Connor PG; Weiss L; Fiellin DA; Fiellin LE
    Drug Alcohol Depend; 2014 Jun; 139():79-85. PubMed ID: 24726429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
    Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine and HIV primary care: new opportunities for integrated treatment.
    Khalsa J; Vocci F; Altice F; Fiellin D; Miller V
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S169-72. PubMed ID: 17109302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.
    Cheever LW; Kresina TF; Cajina A; Lubran R
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S3-6. PubMed ID: 21317591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient perspectives of an integrated program of medical care and substance use treatment.
    Drainoni ML; Farrell C; Sorensen-Alawad A; Palmisano JN; Chaisson C; Walley AY
    AIDS Patient Care STDS; 2014 Feb; 28(2):71-81. PubMed ID: 24428768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence.
    Bridge TP; Fudala PJ; Herbert S; Leiderman DB
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S79-85. PubMed ID: 12738352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment.
    Barbosa-Leiker C; McPherson S; Layton ME; Burduli E; Roll JM; Ling W
    Am J Drug Alcohol Abuse; 2018; 44(4):488-496. PubMed ID: 29672167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Models for integrating buprenorphine therapy into the primary HIV care setting.
    Basu S; Smith-Rohrberg D; Bruce RD; Altice FL
    Clin Infect Dis; 2006 Mar; 42(5):716-21. PubMed ID: 16447120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.